Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2]

News | Stents

Abbott’s Xience Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

April 06, 2021

Videos | Coronavirus (COVID-19)

VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

April 01, 2021

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

Overview of Trials for Anticoagulation Therapy for COVID-19 Patients

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

March 22, 2021

News | Coronavirus (COVID-19)

FDA Clears Third COVID-19 Vaccine From Janssen

March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third ...

March 01, 2021

Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Feature | Coronavirus (COVID-19) | By William Schaffner, M.D., and Allen J. Taylor, M.D.

Cardiologists Should Prioritize Influenza Vaccination Amidst COVID-19 Pandemic

While influenza (flu) is unpredictable, the 2020-2021 influenza season may present an unprecedented dual threat: co ...

February 23, 2021

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

News | Cardiovascular Clinical Studies

Vascular Decalcification as Heart Disease Treatment Examined in $1.8 Million NIH Grant

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

January 27, 2021

FDA clears Verquvo, Vericiguat, Heart failure drug.

News | Heart Failure

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization

January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first ...

January 25, 2021

The U.S. Government promised to have 20 million people vaccinated by Jan. 1, 2021 with just the Pfizer Vaccine. Even with two vaccines now approved, U.S. vaccinations for COVID stand at less than 4.5 million on Jan. 4, 2020. Getty Images The Pfizer and Moderna COVID vaccines were hailed as a major accomplishment in modern science and as the beginning of the end for COVID. This very well may be true, but it absolutely will not happen as fast as the government has led us to believe. #COVID19 #COVID #SARScov2

Blog | Coronavirus (COVID-19)

COVID Vaccines May Make the Future Brighter in 2021, if They Ever Arrive

There was much fanfare over the U.S. Food and Drug Administration (FDA) emergency use authorizations (EUAs) in December ...

January 04, 2021

Who Can Get the COVID-19 Vaccine? Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, a nurse at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

News | Coronavirus (COVID-19) | Dave Fornell, Editor

Who Qualifies for the COVID Vaccine Under CDC Guidelines

The Centers for Disease Control and Prevention (CDC) Dec. 3, released an interim guidance document to federal, state ...

January 04, 2021

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Feature | Coronavirus (COVID-19)

NIH Pauses Anticoagulant Trial For Critically Ill COVID-19 Patients

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

December 23, 2020

The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older. #COVID19 #SARSCoV2 #Vaccine

News | Coronavirus (COVID-19)

FDA Approved Second COVID-19 Vaccine From Moderna

December 23, 2020 — The U.S. Food and Drug Administration December 18 issued an emergency use authorization (EUA) for a ...

December 23, 2020

The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec, 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance. #COVID #COVID19 #SARSCoV2 #vaccine #COVIDVaccine

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

FDA Clears First COVID-19 Vaccine Under an Emergency Use Authorization

December 14, 2020 — The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for ...

December 14, 2020

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

News

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

November 18, 2020

Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

News | Pharmaceuticals

Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors

November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary ...

November 17, 2020

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020

News | Cath Lab

Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

November 16, 2020